Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cancer: early-phase trial registry
279 of 621 indexed Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #6 of 28,707 conditions by registered trial count.
621 US clinical trials · 279 currently recruiting · #6 of 28,707 conditions by registered trial count
Cancer: 621 US clinical trials tracked, 279 recruiting.
Cancer is the subject of 621 registered US clinical trials on ClinicalTrials.gov, 279 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 31 of these trials.
Enrollment posture brief
Registry condition cancer
OPEN 279 | RECR 45% | LATE 31 | EARLY 164 | RANK #6 | SPON 31
Volume-matched condition peers
Nearest open-share peer: Duchenne Muscular Dystrophy (45% recruiting · 49 trials)
Cancer lists 279 open slots (45% of 621 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cancer is recruiting above its size-band peers.
279 of 621 indexed trials (44.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 31 of 621 trials (5%). 270 distinct sponsors appear on at least one study for this condition label.
-
Typical Cancer enrolment sits around 108 participants.
Median target enrolment is 108 among the 616 trials that report a genuine target (sentinel values excluded). 287 of those (46.6%) plan for fewer than 100 participants.
-
Cancer research is mostly interventional.
462 interventional and 159 observational studies make up this index (74.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
621 total, page 10 of 13
Financial Navigation Study Among Young Adult Blood Cancer Survivors
Tufts Medical Center
NCT05620979
Virtual Reality for Cancer Pain Management
Medstar Health Research Institute
NCT04572074
Implementing Personalized Exercise Prescriptions Through Mobile Health in the Elderly Cancer Survivors
University of Minnesota
NCT05069519
Fluorescence Bronchoscopy and Molecular Characterization of Abnormal Bronchial Lesions: Novel Approaches for Early Detection of Lung Cancer in High Risk Patients
National Institute of Environmental Health Sciences (NIEHS)
NCT00512642
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin
NCT02705105
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Stanford University
NCT00375830
Iron Overload in Patients Undergoing Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
NCT00888316
Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial
M.D. Anderson Cancer Center
NCT05041946
Pain Management in Cancer Patients Using a Mobile Application
Massachusetts General Hospital
NCT02069743
PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers
Abramson Cancer Center at Penn Medicine
NCT04616768
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
Saad Jamshed MD
NCT01666782
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
NCT00770536
Pilot Study of a Decision Aid Intervention for Family-building After Cancer
Stanford University
NCT04059237
Investigation of Cisplatin-Related Kidney Toxicity
University of Chicago
NCT00984035
Psychological Intervention for Caregivers of Patients Undergoing Stem Cell Transplant
Massachusetts General Hospital
NCT03328663
A Study of Physical Activity in Cancer Survivors
Mayo Clinic
NCT05988892
Home Parenteral Nutrition in Cancer Patients
Southwestern Regional Medical Center
NCT01152879
Smartphone App for Cancer Medication Adherence
Columbia University
NCT05225090
A Complex Contraception Registry
University of California, San Diego
NCT02219269
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT01292655
Pilot Optimization Trial of Decision Partnering Intervention for Advanced Cancer Family Caregivers
University of Alabama at Birmingham
NCT03947606
Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting
St. Jude Children's Research Hospital
NCT01673243
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
Inovio Pharmaceuticals
NCT00198276
Firefighter Soot, Sauna, and Sweat Excretion Pilot Study
HealthPartners Institute
NCT05256966
Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
Sanofi
NCT00485719
AZD8330 First Time in Man in Patients With Advanced Malignancies
AstraZeneca
NCT00454090
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
University of Pittsburgh
NCT00703976
ARQ 501 in Subjects With Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT00075933
Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors
Sanofi
NCT00777699
Validation of Low Dose CT for Diagnosis of Lung Nodules
Children's Hospital Medical Center, Cincinnati
NCT03681873
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
GlaxoSmithKline
NCT00920257
The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease
St. Jude Children's Research Hospital
NCT01591187
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
NCT00020579
Physical Activity and Healthy Eating Among Young Adult Cancer Survivors
UNC Lineberger Comprehensive Cancer Center
NCT05887401
C-Reactive Protein as a Predictor of Stem Cell Transplant Complications
Ann & Robert H Lurie Children's Hospital of Chicago
NCT00179868
Study of Oral PQR309 in Patients With Advanced Solid Tumors
PIQUR Therapeutics
NCT02483858
A Pilot Feasibility Trial of a Tailored Intervention to Improve Adherence in Adolescents and Young Adults With Cancer
Children's Hospital Medical Center, Cincinnati
NCT05706610
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
Arbutus Biopharma Corporation
NCT01262235
Stepped-Care Telehealth for Distress in Cancer Survivors
Wake Forest University Health Sciences
NCT03060096
Mind-body Resiliency Intervention for Fear of Cancer Recurrence
Massachusetts General Hospital
NCT04876599
Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors
UNC Lineberger Comprehensive Cancer Center
NCT06171945
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Amgen
NCT00413283
A Study of the Alternative Administration of Ixabepilone and Vinflunine
Bristol-Myers Squibb
NCT00362830
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
AbbVie
NCT03941964
Expressive Helping for Chinese-Speaking Cancer Patients and Survivors
New York University
NCT03945734
Cancer Care Coordination for Chemotherapy Patients
University of California, Davis
NCT02238951
Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study)
Fred Hutchinson Cancer Center
NCT03600038
Promoting Quality of Life Among Young Adult Cancer Survivors
Emory University
NCT03446105
Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)
Dana-Farber Cancer Institute
NCT05358951
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Regeneron Pharmaceuticals
NCT01727869
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 116 |
| Phase 2 | 48 |
| Phase 3 | 27 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cancer page
621 registered trials, 279 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 279 Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cancer condition card totals 621 registered trials; most-linked intervention Usual Care; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.